Literature DB >> 15033921

The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.

Hinrich P Hansen1, Andreas Recke, Ulrich Reineke, Bastian Von Tresckow, Peter Borchmann, Elke Pogge Von Strandmann, Hans Lange, Hilmar Lemke, Andreas Engert.   

Abstract

Tumor necrosis factor (TNF)-alpha converting enzyme (TACE) is responsible for the ectodomain release of various membrane proteins by proteolytic cleavage in close proximity to the cell membrane. Despite the wide spectrum of possible substrates, selective cleavage can be achieved by substrate cross-linking. To explore the underlying mechanism, we studied the TACE-mediated shedding of CD30. Whereas the constitutive release of the soluble ectodomain of CD30 (sCD30) from the lymphoma cell line Karpas 299 was enhanced by most anti-CD30 antibodies, it was inhibited by antibodies Ber-H2 and Ki-4. On the basis of the recognized epitopes, shedding seemed to depend on the availability of the cysteine-rich domains (CRD) 2 and 5 of the CD30 ectodomain. CRD2 and 5 have almost identical amino acid sequences and are localized distant from the TACE-targeted cleavage site. Soluble CD30, the product of this enzyme reaction, did not inhibit, but on the contrary, it stimulated CD30 shedding in a CRD2/5-dependent manner. This process could also be induced by CRD2/5-derived peptides but not by a CRD1-derived control peptide. This example of a product-activation was CD30 selective since other TACE substrates such as TNFR1 or TNF-alpha were not affected. These data suggest that CD30 shedding is stimulated by an elevated local availability of CRD2 or 5, possibly by forming a docking station for the releasing enzyme through substrate aggregation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15033921     DOI: 10.1096/fj.03-0901fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

Review 1.  Molecular and cellular mechanisms of ectodomain shedding.

Authors:  Kazutaka Hayashida; Allison H Bartlett; Ye Chen; Pyong Woo Park
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

2.  The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity.

Authors:  Zenda L Woodman; Sylva L U Schwager; Pierre Redelinghuys; Adriana K Carmona; Mario R W Ehlers; Edward D Sturrock
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

3.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

4.  Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing.

Authors:  Igor Pavlov; Thomas B Martins; Julio C Delgado
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

Review 5.  Molecular mechanisms of soluble cytokine receptor generation.

Authors:  Stewart J Levine
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

6.  Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding.

Authors:  Christoph Garbers; Nathalie Jänner; Athena Chalaris; Marcia L Moss; Doreen M Floss; Dörte Meyer; Friedrich Koch-Nolte; Stefan Rose-John; Jürgen Scheller
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

Review 7.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

8.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24

9.  Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model.

Authors:  S Schiffer; H P Hansen; G Hehmann-Titt; M Huhn; R Fischer; S Barth; T Thepen
Journal:  Blood Cancer J       Date:  2013-03-22       Impact factor: 11.037

Review 10.  The ADAM metalloproteinases.

Authors:  Dylan R Edwards; Madeleine M Handsley; Caroline J Pennington
Journal:  Mol Aspects Med       Date:  2008-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.